[Pomalidomide for multiple myeloma].

[Pomalidomide for multiple myeloma].

Bull Cancer. 2017 Jun 02;:

Authors: Dougé A, Lemal R, Chaleteix C

Abstract
Pomalidomide is a second-generation immunomodulatory drug (IMID). Its efficiency overtakes its predecessors' (thalidomide, lenalidomide), with less toxicity. It is indicated in the treatment of refractory or relapsed multiple myeloma, associated to dexamethasone. It is available in France since 2013, following the results of different studies.

PMID: 28583668 [PubMed - as supplied by publisher]

http://ift.tt/2r0Iylz